Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates

分组1 - Ultragenyx reported a quarterly loss of $1.29 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.20, but an improvement from a loss of $1.39 per share a year ago, resulting in an earnings surprise of -7.32% [1] - The company generated revenues of $207 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.01%, and showing an increase from $164.88 million in the same quarter last year [2] - Over the last four quarters, Ultragenyx has surpassed consensus revenue estimates two times, but has only exceeded consensus EPS estimates once [2] 分组2 - The stock's immediate price movement will largely depend on management's commentary during the earnings call, with Ultragenyx shares having increased by approximately 3.8% year-to-date, compared to a 1.4% gain in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.42 on revenues of $166.49 million, and for the current fiscal year, it is -$4.20 on revenues of $777.45 million [7] - The Medical - Biomedical and Genetics industry, to which Ultragenyx belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]